APUS · Apimeds Pharmaceuticals US Inc
United States · RS rating 14 · As of 2026-11-03
| Price | 2.97 USD |
|---|---|
| 1-day change | +2.8% |
| RS rating (overall / 1M / 3M / 12M) | 14 / 9 / 16 / 6 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 28 / 9 / 22 |
| Industry group (rank) | Medical-Generic Drugs (136) |
| EPS growth Q/Q | +47.9% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +92.4% |
| Market cap (USD) | $19.0M |